Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Grants Priority Review To Roche’s Multiple Sclerosis Drug

XTALKS VITALS NEWS

Roche

The Swiss drugmaker is looking to include both relapsing multiple sclerosis and primary progressive multiple sclerosis on the drug’s list of indications.

Share this!

Tweet: Roche’s Ocrevus for #multiplesclerosis has been granted #FDA priority review status http://ctt.ec/azpej+Roche’s Ocrevus for multiple sclerosis has been granted FDA priority review status.

Tweet: Sales of Roche’s Ocrevus are expected to reach between $3 billion and $7 billion http://ctt.ec/yK88B+Sales of Roche’s Ocrevus are expected to reach between $3 billion and $7 billion.

June 29, 2016 | by Sarah Massey, M.Sc.

Roche’s Ocrevus (ocrelizumab), a new drug designed to treat a form of multiple sclerosis for which no treatments are available, has been granted priority review status by the US Food and Drug Administration (FDA). The decision could lead to accelerated approval of the drug, which means the biologic could hit the market by the end of 2016.

The Swiss drugmaker is looking to include both relapsing multiple sclerosis and primary progressive multiple sclerosis on the drug’s list of indications. While there are multiple treatments on the market for relapsing multiple sclerosis – including those from Novartis, Merck, Biogen, Sanofi and Teva – there are no approved treatments for the progressive form of the disease.

It’s estimated that 10 to 15 percent of all patients with multiple sclerosis suffer from the progressive subtype. In clinical trials, Roche’s Ocrevus was a more effective treatment for relapsing multiple sclerosis compared to Merck’s injectable, Rebif. What’s more, the biologic reduced the risk of disability progression in patients with primary progressive multiple sclerosis by 24 percent, over the placebo.

“Ocrevus is the first investigational medicine to significantly reduce disability progression in people with relapsing and primary progressive forms of MS,” said Dr. Sandra Horning, chief medical officer and head of Global Product Development. “We are pleased by the FDA’s decision to classify their review of the biologics license application as priority because we believe Ocrevus has the potential to help people living with either of these two forms of MS. We will continue to work closely with the FDA and European Medicines Agency (EMA) to bring this investigational medicine to people with MS as quickly as possible.”



Roche also expects the drug to win EMA approval by mid-2017. If approved, the drug would be the first to provide a treatment option for 95 percent of all multiple sclerosis patients.

Due to its blockbuster potential, sales of the biologic are expected to reach between $3 billion and $7 billion at its peak. The revenue could prove essential for Roche as many of its cancer drugs may soon face biosimilar competition.

A small French biotech company, MedDay, is currently also developing a biologic for primary progressive multiple sclerosis. Their drug candidate, MD1003, is being tested in a Phase III clinical trial. The company hopes to win European approval for the drug in 2017, with plans to file an FDA application later on.


Keywords: Multiple Sclerosis, FDA, Priority Review


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


FDA Approves Puma Biotechnology’s Extended Adjuvant Therapy for Breast

July 19, 2017 - Puma Biotechnology’s breast cancer drug Nerlynx (neratinib) has been approved by the US Food and Drug Administration (FDA).

Featured In: Biotech News


CAR-T Cell Therapy Shows Promise as Leukemia Treatment in Early Stage Clinical Trial

July 19, 2017 - About 70 percent of clinical trial participants with chronic lymphocytic leukemia experienced tumor shrinkage after being treated with CAR-T immunotherapy, according to researchers at Fred Hutchinson Cancer Research Center.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.